Overview

This trial is active, not recruiting.

Conditions central centrifugal scarring alopecia, lichen planopilaris, discoid lupus erythematosus
Sponsor Wake Forest University
Start date April 2006
End date September 2008
Trial size 25 participants
Trial identifier NCT00691769, 00000301, 31050

Summary

The purpose of this research study is to see if a specific protein that we are interested in is involved in scarring hair loss. If these proteins are involved, further genetic work may also better define the disease as well as future treatment options.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
Arm
CCSA subjects will be recruited from patients who have been diagnosed through biopsy with CCSA and treated with standard of care for up to eight months in the Department of Dermatology clinic of Wake Forest University School of Medicine.
patients with lichen planopilaris (LP) and patients with discoid lupus erythematosus (DLE) will be collected from patients who have been diagnosed through biopsy in the clinic.
Healthy study subjects will be patients from the Wake Forest University School of Medicine Department of Dermatology population undergoing excisions for cosmetic purposes or excision of free margins around tumors that would have otherwise been discarded.

Primary Outcomes

Measure
To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia (CCSA), lichen planopilaris (LP) and discoid lupus erythematosus (DLE) and in healthy controls.
time frame: 8 weeks

Secondary Outcomes

Measure
To evaluate the expression of Fas protein in skin biopsies of participants with central centrifugal scarring alopecia before and after treatment with intralesional and topical steroids.
time frame: 8 weeks

Eligibility Criteria

Female participants at least 30 years old.

Inclusion Criteria: - Participants ages 30 years or older with a biopsy- proven diagnosis of CCSA. - Undergone standard of care treatment for CCSA by a WFUSM Dermatologist - Women of child bearing age will be required to have a negative pregnancy test in order to participate in the study - Participants ages 30 years or older with a biopsy- proven diagnosis of LP. - Participants ages 30 years or older with a biopsy- proven diagnosis of DLE. - Healthy participants must be ages 30 years or older. Exclusion Criteria: - Age less than 30 years of age. - Clinically evident bacterial or viral infection of the scalp. - Pregnant or nursing woman of child-bearing potential. - Participation in any other investigative research study involving study medication. - Inability to return for the biopsy visit.

Additional Information

Official title Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia
Principal investigator Amy McMichael, MD
Description This is a single-center study, designed to evaluate the expression of Fas protein in skin biopsies of patients with scarring alopecia including fourteen patients with central centrifugal scarring alopecia (CCSA), three patients with lichen planopilaris (LP) and three patients with discoid lupus erythematosus (DLE). Skin biopsies of five healthy participants will be used as controls.
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by Wake Forest School of Medicine.